Dyson PJ - Search Results

1

Studies of glutathione transferase P1-1 bound to a platinum(IV)-based anticancer compound reveal the molecular basis of its activation.

Parker LJ, Italiano LC, Morton CJ, Hancock NC, Ascher DB, Aitken JB, Harris HH, Campomanes P, Rothlisberger U, De Luca A, Lo Bello M, Ang WH, Dyson PJ, Parker MW. Parker LJ, et al. Among authors: dyson pj. Chemistry. 2011 Jul 4;17(28):7806-16. doi: 10.1002/chem.201100586. Epub 2011 Jun 16. Chemistry. 2011. PMID: 21681839

2

Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance.

Ang WH, Khalaila I, Allardyce CS, Juillerat-Jeanneret L, Dyson PJ. Ang WH, et al. Among authors: dyson pj. J Am Chem Soc. 2005 Feb 9;127(5):1382-3. doi: 10.1021/ja0432618. J Am Chem Soc. 2005. PMID: 15686364

3

Synthesis and characterization of platinum(IV) anticancer drugs with functionalized aromatic carboxylate ligands: influence of the ligands on drug efficacies and uptake.

Ang WH, Pilet S, Scopelliti R, Bussy F, Juillerat-Jeanneret L, Dyson PJ. Ang WH, et al. Among authors: dyson pj. J Med Chem. 2005 Dec 15;48(25):8060-9. doi: 10.1021/jm0506468. J Med Chem. 2005. PMID: 16335930

4

Ionic solid-state dimers and polymers derived from imidazolium dicarboxylic acids.

Fei Z, Ang WH, Geldbach TJ, Scopelliti R, Dyson PJ. Fei Z, et al. Among authors: dyson pj. Chemistry. 2006 May 15;12(15):4014-20. doi: 10.1002/chem.200500944. Chemistry. 2006. PMID: 16534825

5

Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.

Ang WH, Daldini E, Scolaro C, Scopelliti R, Juillerat-Jeannerat L, Dyson PJ. Ang WH, et al. Among authors: dyson pj. Inorg Chem. 2006 Oct 30;45(22):9006-13. doi: 10.1021/ic061008y. Inorg Chem. 2006. PMID: 17054361

6

A strategy for the synthesis of transition-metal nanoparticles and their transfer between liquid phases.

Zhao D, Fei Z, Ang WH, Dyson PJ. Zhao D, et al. Among authors: dyson pj. Small. 2006 Jul;2(7):879-83. doi: 10.1002/smll.200500317. Small. 2006. PMID: 17193138 No abstract available.

7

Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms.

Vock CA, Ang WH, Scolaro C, Phillips AD, Lagopoulos L, Juillerat-Jeanneret L, Sava G, Scopelliti R, Dyson PJ. Vock CA, et al. Among authors: dyson pj. J Med Chem. 2007 May 3;50(9):2166-75. doi: 10.1021/jm070039f. Epub 2007 Apr 10. J Med Chem. 2007. PMID: 17419606

8

Revisiting ether-derivatized imidazolium-based ionic liquids.

Fei Z, Ang WH, Zhao D, Scopelliti R, Zvereva EE, Katsyuba SA, Dyson PJ. Fei Z, et al. Among authors: dyson pj. J Phys Chem B. 2007 Aug 30;111(34):10095-108. doi: 10.1021/jp073419l. Epub 2007 Aug 3. J Phys Chem B. 2007. PMID: 17676796

9

Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs.

Ang WH, De Luca A, Chapuis-Bernasconi C, Juillerat-Jeanneret L, Lo Bello M, Dyson PJ. Ang WH, et al. Among authors: dyson pj. ChemMedChem. 2007 Dec;2(12):1799-806. doi: 10.1002/cmdc.200700209. ChemMedChem. 2007. PMID: 17918761

10

Strategy to tether organometallic ruthenium-arene anticancer compounds to recombinant human serum albumin.

Ang WH, Daldini E, Juillerat-Jeanneret L, Dyson PJ. Ang WH, et al. Among authors: dyson pj. Inorg Chem. 2007 Oct 29;46(22):9048-50. doi: 10.1021/ic701474m. Epub 2007 Oct 5. Inorg Chem. 2007. PMID: 17918830

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

473 results

Search Page

Filters